Novel developments in the prophylaxis and treatment of acute GVHD

2.

Koyama

M

,

Mukhopadhyay

P

,

Schuster

IS

, et al.

MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota

.

Immunity

.

2019

. ;

51

:

885

-

898

.

3.

Schwab

L

,

Goroncy

L

,

Palaniyandi

S

, et al.

Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance GvHD via tissue damage

.

Nat Med

.

2014

. ;

20

:

648

-

654

.

4.

Zeiser

R

,

Blazar

BR

.

Acute graft-versus-host disease - biologic process, prevention, and therapy

.

N Engl J Med

.

2017

. ;

377

:

2167

-

2179

.

5.

Wilhelm

K

,

Ganesan

J

,

Müller

T

, et al.

Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R

.

Nat Med

.

2010

. ;

16

(

12

):

1434

-

1438

.

6.

Jankovic

D

,

Ganesan

J

,

Bscheider

M

, et al.

The Nlrp3 inflammasome regulates acute graft-versus-host disease

.

J Exp Med

.

2013

. ;

210

(

10

):

1899

-

1910

.

7.

Kono

H

,

Chen

CJ

,

Ontiveros

F

,

Rock

KL

.

Uric acid promotes an acute inflammatory response to sterile cell death in mice

.

J Clin Invest

.

2010

. ;

120

(

6

):

1939

-

1949

.

8.

Ratanatharathorn

V

,

Nash

RA

,

Przepiorka

D

, et al.

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation

.

Blood

.

1998

. ;

92

(

7

):

2303

-

2314

.

9.

Filipovich

AH

,

Weisdorf

D

,

Pavletic

S

, et al.

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: diagnosis and staging working group report

.

Biol Blood Marrow Transplant

.

2005

. ;

11

(

12

):

945

-

956

.

10.

Glucksberg

H

,

Storb

R

,

Fefer

A

, et al.

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

.

Transplantation

.

1974

. ;

18

(

4

):

295

-

304

.

11.

Rowlings

PA

,

Przepiorka

D

,

Klein

JP

, et al.

IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade

.

Br J Haematol

.

1997

. ;

97

(

4

):

855

-

864

.

12.

Harris

AC

,

Young

R

,

Devine

S

, et al.

International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium

.

Biol Blood Marrow Transplant

.

2016

. ;

22

(

1

):

4

-

10

.

13.

Lee

SE

,

Cho

BS

,

Kim

JH

, et al.

Risk and prognostic factors for acute GVHD based on NIH consensus criteria

.

Bone Marrow Transplant

.

2013

. ;

48

(

4

):

587

-

592

.

14.

Jagasia

M

,

Arora

M

,

Flowers

ME

, et al.

Risk factors for acute GVHD and survival after hematopoietic cell transplantation

.

Blood

.

2012

. ;

119

(

1

):

296

-

307

.

15.

Westin

JR

,

Saliba

RM

,

De Lima

M

, et al.

Steroid-refractory acute GVHD: predictors and outcomes

.

Adv Hematol

.

2011

. ;

2011

:

601953

.

16.

MacMillan

ML

,

Weisdorf

DJ

,

Wagner

JE

, et al.

Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems

.

Biol Blood Marrow Transplant

.

2002

. ;

8

(

7

):

387

-

394

.

17.

Zeiser

R

,

von Bubnoff

N

,

Butler

J

, et al.

Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease

.

N Engl J Med

.

2020

. ;

382

(

19

):

1800

-

1810

.

18.

Biavasco

F

,

Ihorst

G

,

Wäsch

R

, et al.

Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract

.

Bone Marrow Transplant

.

2022

. ;

57

(

10

):

1500

-

1506

.

19.

Mrsić

M

,

Labar

B

,

Bogdanić

V

, et al.

Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia

.

Bone Marrow Transplant

.

1990

. ;

6

(

2

):

137

-

141

.

20.

Kröger

N

,

Solano

C

,

Wolschke

C

, et al.

Antilymphocyte globulin for prevention of chronic graft-versus-host disease

.

N Engl J Med

.

2016

. ;

374

(

1

):

43

-

53

.

21.

Nash

RA

,

Antin

JH

,

Karanes

C

, et al.

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors

.

Blood

.

2000

. ;

96

(

6

):

2062

-

2068

.

22.

Cutler

C

,

Logan

B

,

Nakamura

R

, et al.

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

.

Blood

.

2014

. ;

124

(

8

):

1372

-

1377

.

23.

Finke

J

,

Bethge

WA

,

Schmoor

C

, et al.

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

.

Lancet Oncol

.

2009

. ;

10

(

9

):

855

-

864

.

24.

Soiffer

RJ

,

Kim

HT

,

McGuirk

J

, et al.

Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation

.

J Clin Oncol

.

2017

. ;

35

(

36

):

4003

-

4011

.

25.

Walker

I

,

Panzarella

T

,

Couban

S

, et al.

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

.

Lancet Oncol

.

2016

. ;

17

(

2

):

164

-

173

.

26.

Admiraal

R

,

Nierkens

S

,

de Witte

MA

, et al.

Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis

.

Lancet Haematol

.

2017

. ;

4

(

4

):

e183

-

e191

.

27.

Dabas

R

,

Jamani

K

,

Kangarloo

SB

, et al.

Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulin

.

Blood Adv

.

2019

. ;

3

(

9

):

1394

-

1405

.

28.

Arslan

S

,

Al Malki

MM

.

New strategies for mismatched unrelated donor (MMUD) hematopoietic cell transplant (HCT)

.

Hematology

.

2022

. ;

2022

(

1

):

74

-

82

.

29.

Al Malki

MM

,

Tsai

N-C

,

Palmer

J

, et al.

Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant

.

Blood Adv

.

2021

. ;

5

(

12

):

2650

-

2659

.

30.

Watkins

B

,

Qayed

M

,

McCracken

C

, et al.

Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD

.

J Clin Oncol

.

2021

. ;

39

(

17

):

1865

-

1877

.

31.

Luznik

L

,

O'Donnell

PV

,

Symons

HJ

, et al.

HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide

.

Biol Blood Marrow Transplant

.

2008

. ;

14

(

6

):

641

-

650

.

32.

Bolaños-Meade

J

,

Hamadani

M

,

Wu

J

, et al.

Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis

.

N Engl J Med

.

2023

. ;

388

(

25

):

2338

-

2348

.

33.

Broers

AEC

,

de Jong

CN

,

Bakunina

K

, et al.

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial

.

Blood Adv

.

2022

. ;

6

(

11

):

3378

-

3385

.

34.

Goldsmith

SR

,

Abid

MB

,

Auletta

JJ

, et al.

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

.

Blood

.

2021

. ;

137

(

23

):

3291

-

3305

.

35.

Jamy

O

,

Hebert

C

,

Dunn-Valadez

S

, et al.

Risk of cytomegalovirus infection with post-transplantation cyclophosphamide in haploidentical and HLA-matched unrelated donor transplantation

.

Transplant Cell Ther

.

2022

. ;

28

(

4

):

213.e1

-

213.e6

.

36.

Chen

YB

,

Kim

HT

,

McDonough

S

, et al.

Up-regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation

.

Biol Blood Marrow Transplant

.

2009

. ;

15

(

9

):

1066

-

1076

.

37.

Chen

YB

,

McDonough

S

,

Chen

H

, et al.

Expression of α4β7 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHD

.

Bone Marrow Transplant

.

2013

. ;

48

(

4

):

598

-

603

.

38.

Fløisand

Y

,

Lazarevic

VL

,

Maertens

J

, et al.

Safety and effectiveness of vedolizumab in patients with steroid-refractory gastrointestinal acute graft-versus-host disease: a retrospective record review

.

Biol Blood Marrow Transplant

.

2019

. ;

25

(

4

):

720

-

727

.

39.

Chen

Y-B

,

Mohty

M

,

Zeiser

R

, et al. Vedolizumab for prophylaxis of lower gastrointestinal (GI) acute graft-versus-host disease (aGvHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) from unrelated donors: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study (GRAPHITE). Paper presented at: Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.

15-19 February 2023

. . Orlando, FL.

40.

Sandmaier

BM

,

Kornblit

B

,

Storer

BE

, et al.

Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial

.

Lancet Haematol

.

2019

. ;

6

(

8

):

e409

-

e418

.

41.

Armand

P

,

Kim

HT

,

Sainvil

M-M

, et al.

The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial

.

Br J Haematol

.

2016

. ;

173

(

1

):

96

-

104

.

42.

Shaw

BE

,

Jimenez-Jimenez

AM

,

Burns

LJ

, et al.

National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide

.

J Clin Oncol

.

2021

. ;

39

(

18

):

1971

-

1982

.

43.

Hoover

A

,

O’Leary

D

,

Cao

Q

, et al.

Phase II study of myeloablative 8/8- or 7/8-matched allotransplantation with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil: marked reduction in GVHD risk without increased relapse risk compared to historical cyclosporine/methotrexate [abstract]

.

Blood

.

2022

. ;

140

(

suppl 1

):

282

-

283

.

44.

Luznik

L

,

Pasquini

MC

,

Logan

B

, et al.

Randomized phase III BMT CTN trial of calcineurin inhibitor–free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies

.

J Clin Oncol

.

2022

. ;

40

(

4

):

356

-

368

.

45.

Wang

Y

,

Wu

D-P

,

Liu

Q-F

, et al.

Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients

.

J Hematol Oncol

.

2019

. ;

12

(

1

):

88

.

46.

McAdams

MJ

,

Hyder

M

,

Dimitrova

D

, et al.

Phase I/II study of reduced dosing of post-transplantation cyclophosphamide (PTCy) after HLA-haploidentical bone marrow transplantation [abstract]

.

Blood

.

2021

. ;

138

(

suppl 1

):

101

.

47.

Jamy

O

,

Innis-Shelton

R

,

Bal

S

, et al.

Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation

.

Am J Hematol

.

2021

. ;

96

(

10

):

E396

-

e398

.

48.

Al-Homsi

ASS

,

Cirrone

F

,

Cole

K

, et al.

Post-transplant cyclophosphamide, abatacept, and short course of tacrolimus combination (CAST) is safe and seems highly effective in preventing graft-versus-host disease following haploidentical peripheral blood stem cell transplantation [abstract]

.

Blood

.

2021

. ;

138(suppl 1)

:

3906

.

49.

Zeiser

R

,

Polverelli

N

,

Ram

R

, et al.

Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease

.

N Engl J Med

.

2021

. ;

385

(

3

):

228

-

238

.

50.

Morozova

EV

,

Barabanshikova

MV

,

Moiseev

IS

, et al.

A prospective pilot study of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and ruxolitinib in patients with myelofibrosis

.

Acta Haematol

.

2021

. ;

144

(

2

):

158

-

165

.

51.

Abboud

R

,

Gao

F

,

Rettig

MP

, et al.

A single-arm, open-label, pilot study of the JAK1 selective inhibitor itacitinib for the prophylaxis of graft-versus-host disease and cytokine release syndrome in T-cell replete haploidentical peripheral blood hematopoietic cell transplantation [abstract]

.

Blood

.

2021

. ;

138 (suppl 1)

:

100

.

52.

Ali

H

,

Yang

D

,

Mokhtari

S

, et al.

Phase IIa study of adding itacitinib to tacrolimus/sirolimus GVHD prophylaxis after fludarabine/melphalan-based conditioning hematopoietic cell transplantation for acute leukemias, myelodysplastic syndrome, or myelofibrosis [abstract]

.

Blood

.

2022

. ;

140

(

suppl 1

):

1872

-

1874

.

53.

Ali

H

,

Tsai

NC

,

Synold

T

, et al.

Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

.

Blood Adv

.

2022

. ;

6

(

5

):

1444

-

1453

.

54.

Hobbs

G

,

Kim

HT

,

Bottoms

AS

, et al.

A phase II study of ruxolitinib pre-, during- and post-hematopoietic cell transplantation for patients with primary or secondary myelofibrosis [abstract]

.

Blood

.

2021

. ;

138

(

suppl 1

):

169

.

55.

DeFilipp

Z

,

Kim

HT

,

Knight

L

, et al. Prolonged post-transplant ruxolitinib therapy is associated with protection from severe GVHD after allogeneic HCT. Paper presented at: Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.

24 April 2022

. . Salt Lake City, UT.

56.

Meyer

E

,

Pavlova

A

,

Gandhi

A

, et al.

CT-524 Orca-T, a precision engineered allograft, results in high GVHD-free and relapse-free survival following myeloablative conditioning for hematological malignancies

.

Clin Lymphoma Myeloma Leukemia

.

2022

. ;

22

:

S447

.

57.

Salhotra

A

,

Srour

SA

,

Hoeg

RT

, et al.

Orca-Q demonstrates favorable GvHD-and-relapse-free survival in haploidentical transplants without post-transplant cyclophosphamide [abstract]

.

Blood

.

2022

. ;

140

(

suppl 1

):

1865

-

1866

.

58.

Magenau

JM

,

Goldstein

SC

,

Peltier

D

, et al.

α(1)-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease

.

Blood

.

2018

. ;

131

(

12

):

1372

-

1379

.

59.

Kim

HT

,

Logan

B

,

Weisdorf

DJ

.

Novel composite endpoints after allogeneic hematopoietic cell transplantation

.

Transplant Cell Ther

.

2021

. ;

27

(

8

):

650

-

657

.

60.

Holtan

SG

,

DeFor

TE

,

Lazaryan

A

, et al.

Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation

.

Blood

.

2015

. ;

125

(

8

):

1333

-

1338

.

61.

MacMillan

ML

,

DeFor

TE

,

Weisdorf

DJ

.

The best endpoint for acute GVHD treatment trials

.

Blood

.

2010

. ;

115

(

26

):

5412

-

5417

.

62.

Sengsayadeth

S

,

Savani

BN

,

Jagasia

M

, et al.

Six-month freedom from treatment failure is an important end point for acute GVHD clinical trials

.

Bone Marrow Transplant

.

2014

. ;

49

(

2

):

236

-

240

.

63.

Martin

PJ

,

Rizzo

JD

,

Wingard

JR

, et al.

First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation

.

Biol Blood Marrow Transplant

.

2012

. ;

18

(

8

):

1150

-

1163

.

64.

Zeiser

R

,

Socié

G

,

Schroeder

MA

, et al.

Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial

.

Lancet Haematol

.

2022

. ;

9

(

1

):

e14

-

e25

.

65.

Bolaños-Meade

J

,

Logan

BR

,

Alousi

AM

, et al.

Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802

.

Blood

.

2014

. ;

124

(

22

):

3221

-

3227

.

66.

Cragg

L

,

Blazar

BR

,

Defor

T

, et al.

A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease

.

Biol Blood Marrow Transplant

.

2000

. ;

6

(

4a

):

441

-

447

.

67.

Couriel

DR

,

Saliba

R

,

de Lima

M

, et al.

A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease

.

Biol Blood Marrow Transplant

.

2009

. ;

15

(

12

):

1555

-

1562

.

68.

Lee

SJ

,

Zahrieh

D

,

Agura

E

, et al.

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial

.

Blood

.

2004

. ;

104

(

5

):

1559

-

1564

.

69.

MacMillan

ML

,

Robin

M

,

Harris

AC

, et al.

A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality

.

Biol Blood Marrow Transplant

.

2015

. ;

21

(

4

):

761

-

767

.

70.

Srinagesh

HK

,

Özbek

U

,

Kapoor

U

, et al.

The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease

.

Blood Adv

.

2019

. ;

3

(

23

):

4034

-

4042

.

71.

Spałek

A

,

Wieczorkiewicz-Kabut

A

,

Koclęga

A

, et al.

Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience

.

Int J Hematol

.

2022

. ;

116

(

6

):

922

-

928

.

72.

Abedin

S

,

Rashid

N

,

Schroeder

M

, et al.

Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis

.

Br J Haematol

.

2021

. ;

195

(

3

):

429

-

432

.

73.

Hill

GR

,

Koyama

M

.

Cytokines and costimulation in acute graft-versus-host disease

.

Blood

.

2020

. ;

136

(

4

):

418

-

428

.

74.

Rafei

H

,

Jenq

RR

.

Microbiome-intestine cross talk during acute graft-versus-host disease

.

Blood

.

2020

. ;

136

(

4

):

401

-

409

.

75.

Voermans

C

,

Hazenberg

MD

.

Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance

.

Blood

.

2020

. ;

136

(

4

):

410

-

417

.

76.

Zeiser

R

.

Introduction to a review series on pathophysiology and treatment of acute GVHD

.

Blood

.

2020

. ;

136

(

4

):

375

-

376

.

77.

Etra

A

,

Capellini

A

,

Alousi

A

, et al.

Effective treatment of low-risk acute GVHD with itacitinib monotherapy

.

Blood

.

2023

. ;

141

(

5

):

481

-

489

.

78.

Pidala

J

,

Hamadani

M

,

Dawson

P

, et al.

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

.

Blood

.

2020

. ;

135

(

2

):

97

-

107

.

79.

Koreth

J

,

Loren

AW

,

Nakamura

R

, et al. Final safety and efficacy results from Equate, an open-label study evaluating itolizumab, a novel targeted anti-CD6 therapy, in newly diagnosed acute graft-versus-host disease. Paper presented at: Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.

16 February 2023

. . Orlando, FL.

80.

Ponce

DM

,

Alousi

AM

,

Nakamura

R

, et al.

A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract

.

Blood

.

2023

. ;

141

(

12

):

1389

-

1401

.

81.

Kekre

N

,

Kim

HT

,

Hofer

J

, et al.

Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease

.

Bone Marrow Transplant

.

2021

. ;

56

(

5

):

1006

-

1012

.

82.

Al Malki

MM

,

London

K

,

Baez

J

, et al.

Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

.

Blood Adv

.

2023

. .

83.

Ferrara

JLM

,

Prado Acosta

M

,

Jeong

S

, et al.

Inhibition of the receptor interactive protein kinase 1 (RIP1) pathway prevents acute GVHD [abstract]

.

Blood

.

2022

. ;

140

(

suppl 1

):

7330

-

7331

.

84.

Abedin

S

,

Hamadani

M

,

Holtan

SG

, et al.

Neihulizumab (ALTB-168) in patients with steroid-refractory acute graft-versus-host-disease (SR-aGVHD) or treatment-refractory acute graft-versus-host-disease (TR-aGVHD) [abstract]

.

Blood

.

2022

. ;

140

(

suppl 1

):

10495

-

10497

.

85.

Norona

J

,

Apostolova

P

,

Schmidt

D

, et al.

Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans

.

Blood

.

2020

. ;

136

(

12

):

1442

-

1455

.

86.

Zeiser

R

,

Chen

YB

,

Youssef

NN

,

Ayuk

F

.

Pathophysiology of gastrointestinal acute graft-versus-host disease and the potential role of glucagon-like peptide 2

.

Br J Haematol

.

2023

. ;

201

(

4

):

620

-

627

.

87.

Snyder

KJ

,

Choe

HK

,

Gao

Y

, et al.

Inhibition of bromodomain and extra terminal (BET) domain activity modulates the IL-23R/IL-17 axis and suppresses acute graft-versus-host disease: original research

.

Front Oncol

.

2021

. ;

11

:

760789

.

88.

Holtan

SG

,

Hoeschen

AL

,

Cao

Q

, et al.

Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor

.

Blood Adv

.

2020

. ;

4

(

7

):

1284

-

1295

.

89.

Kakihana

K

,

Fujioka

Y

,

Suda

W

, et al.

Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut

.

Blood

.

2016

. ;

128

(

16

):

2083

-

2088

.

90.

Abedin

S

,

Hamadani

M

.

Experimental pharmaceuticals for steroid-refractory acute graft-versus-host disease

.

J Exp Pharmacol

.

2020

. ;

12

:

549

-

557

.

91.

Qiao

X

,

Biliński

J

,

Wang

L

, et al.

Safety and efficacy of fecal microbiota transplantation in the treatment of graft-versus-host disease

.

Bone Marrow Transplant

.

2023

. ;

58

(

1

):

10

-

19

.

92.

Liu

Y

,

Zhao

Y

,

Qi

J

, et al.

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD

.

Exp Hematol Oncol

.

2022

. ;

11

(

1

):

96

.